Precision Myeloma Care: Genomic Insights Across Precursor, Nonsecretory, and Extramedullary Disease

Precision medicine is reshaping the management of multiple myeloma by integrating genomic profiling, advanced disease monitoring, and biologic characterization across diverse disease states. This session will explore emerging genomic insights that distinguish indolent precursor conditions from high-risk disease, enabling more refined risk stratification and earlier intervention strategies. Dr. Bustoros will review evolving approaches to nonsecretory and oligosecretory myeloma, including the use of measurable residual disease assessment, advanced imaging, and mass spectrometry-based monitoring. The program will also examine the unique biology of extramedullary myeloma and its implications for treatment selection, highlighting recent data on immune-based therapies and dual-target approaches. Attendees will gain practical insights into applying precision diagnostics and genomics to optimize individualized care across the myeloma continuum.